Annual Working Capital
$10.77 M
-$9.90 M-47.90%
31 December 2023
Summary:
Inhibikase Therapeutics annual working capital is currently $10.77 million, with the most recent change of -$9.90 million (-47.90%) on 31 December 2023. During the last 3 years, it has risen by +$711.60 thousand (+7.07%). IKT annual working capital is now -71.96% below its all-time high of $38.42 million, reached on 31 December 2021.IKT Working Capital Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Working Capital
-$717.40 K
-$5.62 M-114.65%
30 September 2024
Summary:
Inhibikase Therapeutics quarterly working capital is currently -$717.40 thousand, with the most recent change of -$5.62 million (-114.65%) on 30 September 2024. Over the past year, it has dropped by -$15.53 million (-104.84%). IKT quarterly working capital is now -101.52% below its all-time high of $47.30 million, reached on 30 June 2021.IKT Quarterly Working Capital Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IKT Working Capital Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -47.9% | -104.8% |
| 3 y3 years | +7.1% | -101.7% |
| 5 y5 years | +554.0% | - |
IKT Working Capital High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -72.0% | +7.1% | -101.7% | at low |
| 5 y | 5 years | -72.0% | +355.4% | -101.5% | +87.8% |
| alltime | all time | -72.0% | +355.4% | -101.5% | +87.8% |
Inhibikase Therapeutics Working Capital History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | -$717.40 K(-114.6%) |
| June 2024 | - | $4.90 M(-25.5%) |
| Mar 2024 | - | $6.57 M(-39.0%) |
| Dec 2023 | $10.77 M(-47.9%) | $10.77 M(-27.3%) |
| Sept 2023 | - | $14.81 M(-23.1%) |
| June 2023 | - | $19.25 M(-22.9%) |
| Mar 2023 | - | $24.96 M(+20.7%) |
| Dec 2022 | $20.68 M | $20.68 M(-16.5%) |
| Sept 2022 | - | $24.77 M(-15.9%) |
| June 2022 | - | $29.46 M(-13.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2022 | - | $34.01 M(-11.5%) |
| Dec 2021 | $38.42 M(+281.8%) | $38.42 M(-11.0%) |
| Sept 2021 | - | $43.16 M(-8.8%) |
| June 2021 | - | $47.30 M(+471.1%) |
| Mar 2021 | - | $8.28 M(-17.7%) |
| Dec 2020 | $10.06 M(-338.5%) | $10.06 M(-271.0%) |
| Sept 2020 | - | -$5.88 M(+29.6%) |
| June 2020 | - | -$4.54 M(+3.2%) |
| Mar 2020 | - | -$4.40 M(+4.3%) |
| Dec 2019 | -$4.22 M(+77.7%) | -$4.22 M |
| Dec 2018 | -$2.37 M | - |
FAQ
- What is Inhibikase Therapeutics annual working capital?
- What is the all time high annual working capital for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics annual working capital year-on-year change?
- What is Inhibikase Therapeutics quarterly working capital?
- What is the all time high quarterly working capital for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics quarterly working capital year-on-year change?
What is Inhibikase Therapeutics annual working capital?
The current annual working capital of IKT is $10.77 M
What is the all time high annual working capital for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high annual working capital is $38.42 M
What is Inhibikase Therapeutics annual working capital year-on-year change?
Over the past year, IKT annual working capital has changed by -$9.90 M (-47.90%)
What is Inhibikase Therapeutics quarterly working capital?
The current quarterly working capital of IKT is -$717.40 K
What is the all time high quarterly working capital for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high quarterly working capital is $47.30 M
What is Inhibikase Therapeutics quarterly working capital year-on-year change?
Over the past year, IKT quarterly working capital has changed by -$15.53 M (-104.84%)